772311-98-5

Basic information

• Product Name: 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE
• Synonyms: 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE;4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE, 95+%;{4-[(2-methyl-1H-imidazol-1-yl)methyl]phenyl}amine;4-[(2-methyl-1H-imidazol-1-yl)methyl]aniline(SALTDATA: FREE);4-[(2-methyl-1-imidazolyl)methyl]aniline;4-[(2-methylimidazol-1-yl)methyl]aniline
• CAS NO: 772311-98-5
• Molecular Formula: C₁₁H₁₃N₃
• Molecular Weight: 187.24
• Mol File: 772311-98-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 372.555°C at 760 mmHg
• Flash Point: 179.115°C
• Appearance: /
• Density: 1.141g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.76±0.31(Predicted)
• CAS DataBase Reference: 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE(772311-98-5)
• EPA Substance Registry System: 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE(772311-98-5)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 772311-98-5(Hazardous Substances Data)

Usage

General Description

4-(2-Methylimidazol-1-ylmethyl)phenylamine is a chemical compound with the molecular formula C12H15N3. 4-(2-METHYLIMIDAZOL-1-YLMETHYL)PHENYLAMINE is a derivative of phenylamine and contains a methylimidazole group. It is commonly used in pharmaceutical research and drug development as a building block for the synthesis of various chemical compounds. The specific properties and uses of this compound may vary depending on the context and the intended application.

InChI:InChI=1/C11H13N3/c1-9-13-6-7-14(9)8-10-2-4-11(12)5-3-10/h2-7H,8,12H2,1H3

Upstream product

• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 56643-86-8 4-(2-Methylimidazol-1-ylmethyl)nitrobenzene 

Downstream Products

• 1147015-38-0 1-isopropyl-7-((2-(4-((2-methyl-1H-imidazol-1-yl)methyl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)ethynyl)-1H-indole-3-carbonitrile 
• 1142947-77-0 1-(4-((2-methyl-1H-imidazol-1-yl)methyl)phenyl)guanidine 
• 1147015-37-9 ⁽⁰⁸¹⁾C₀₇₅₀₆ 
• 1147015-36-8 2-[4-(2-methyl-imidazol-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-ol 
• 1143571-99-6 (E)-tert-butyl (tert-butoxycarbonylamino)(4-((2-methyl-1H-imidazol-1-yl)methyl)phenylamino)methylenecarbamate 
• 125665-48-7 N-[4-(2-Methyl-imidazol-1-ylmethyl)-phenyl]-phthalamic acid 

Relevant articles and documents

Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML

Bruton's tyrosine kinase (BTK) is a member of the Tec kinase family and plays a key role in the modulation of the B-cell receptor (BCR)-mediated signaling pathway. Inhibition of BTK has been proven to be an effective therapeutic approach for various hemat

The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives

A new class of potent antihypertensives has been discovered that exert their effect through blockade of the angiotensin II (AII) receptor.Most AII antagonists reported so far are peptide mimics of the endogenous vasoconstrictor octapeptide angiotensin II.The compounds of this paper are nonpeptides and therefore constitute a new class of potent AII receptor antagonists.Based on the overlap of a conformation of AII with literature lead 3, a hypothesis was developed suggesting the need for an additional acidic functionality to increase the lead's potency.The substitution of an additional carboxylic acid resulted in a 10-fold increase in binding affinity observed for diacid 4.The binding affinities for subsequent compounds were eventually increased 1000-fold over that of the literature leads through a systematic SAR study.Thus the AII receptor binding affinity 50 (μM)> of 15 μM for literature lead 1, for example, was increased to 0.018 and 0.012 μM for compounds 33 and 53.A structure-affinity relationship has been found requiring the presence of four key elements for good activity: (1) an additional phenyl ring at the N-benzyl para position of the benzylimidazole nucleus, (2) an acidic functionality at the ortho position of the terminal aromatic ring, (3) a lipophilic side chain at the imidazole 2-position of three to five carbon atoms in length, and (4) a group at the imidazole 5-position capable of hydrogen bonding.The synthesis as well as the pharmacological activity of the compounds in this new series of AII receptor antagonists are presented.